Our vision is to establish a new standard of care for patients suffering with iron deficiency and iron deficiency anemia.
Iron deficiency anemia afflicts a subset of the two billion people worldwide who are nutritionally iron deficientREF. Approximately 10 million people are iron deficient in the United States, including 5 million who have iron deficiency anemia.
Ferric Pyrophosphate Citrate (FPC)
Our innovative therapeutic was developed to replace iron loss in patients with anemia in an entirely different way. Our unique and differentiated molecule, Ferric Pyrophosphate Citrate (FPC), provides a novel mechanism of action with a physiologic approach. FPC donates iron directly to circulating transferrin making it immediately bioavailable for critical body processes, which allows the body to use the iron in a physiologic manner.
This novel approach to the treatment of iron deficiency and anemia has the potential for application in many disease states.
Access our investor center to learn about our strategies to deliver value for the patients we serve, the medical community, our employees and shareholders.
Access Now